DCR AUD
Alternative Names: DCR-A1203; DCR-AUD; NN 6020Latest Information Update: 09 Apr 2024
At a glance
- Originator Dicerna Pharmaceuticals
- Class Amino sugars; Drug conjugates; Hepatoprotectants; Small interfering RNA
- Mechanism of Action Aldehyde dehydrogenase 2 inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alcoholism
Most Recent Events
- 29 Jan 2023 Dicerna Pharmaceuticals initiates a phase I clinical trial for Alcoholism (In volunteers) in USA (SC) (NCT05845398)
- 31 Dec 2022 Dicerna Pharmaceuticals completes a phase I single-ascending-dose trial for Alcoholism (In volunteers) in USA (SC) (NCT05021640)
- 28 Dec 2021 Dicerna Pharmaceuticals has been acquired by Novo Nordisk